HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants-Reference-Cited by-同舟云学术

HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants

Published:2018-09 Issue:9 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Smith Steven J.¹,Zhao Xue Zhi²,Burke Terrence R.²,Hughes Stephen H.¹

Affiliation:

1. HIV Dynamics and Replication Program, National Cancer Institute—Frederick, National Institutes of Health, Frederick, Maryland, USA

2. Chemical Biology Laboratory, National Cancer Institute—Frederick, National Institutes of Health, Frederick, Maryland, USA

Abstract

Integrase strand transfer inhibitors (INSTIs) have emerged as clinically effective therapeutics that inhibit HIV-1 replication by blocking the strand transfer reaction catalyzed by HIV-1 integrase (IN). Of the three FDA-approved INSTIs, dolutegravir (DTG) is the least apt to select for resistance.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01035-18

Reference35 articles.

1. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA.

2. HIV-1 DNA integration: Mechanism of viral DNA cleavage and DNA strand transfer

3. Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells